董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Konstantin Poukalov | 男 | Director | 37 | 未披露 | 未持股 | 2021-01-27 |
| Roderick Wong | 男 | Director | 43 | 未披露 | 未持股 | 2021-01-27 |
| Jean Frederic Colombel | 男 | Director | 64 | 未披露 | 未持股 | 2021-01-27 |
| Josep Bassaganya Riera | 男 | Chairman, President, Chief Executive Officer and Common Stock Director | 46 | 176.18万美元 | 未持股 | 2021-01-27 |
| Christopher Garabedian | 男 | Director | 54 | 未披露 | 未持股 | 2021-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josep Bassaganya Riera | 男 | Chairman, President, Chief Executive Officer and Common Stock Director | 46 | 176.18万美元 | 未持股 | 2021-01-27 |
| Raquel Hontecillas | 女 | Chief Scientific Officer | 49 | 90.88万美元 | 未持股 | 2021-01-27 |
| Jyoti Chauhan | 女 | Executive Director, Global Clinical Operations and Regulatory Compliance | 32 | 96.14万美元 | 未持股 | 2021-01-27 |
董事简历
中英对照 | 中文 | 英文- Konstantin Poukalov
-
Konstantin Poukalov自2019年10月起担任LianBio董事会执行主席。Poukalov先生自2019年3月起担任Perceptive Advisors(一家专注于生命科学的投资公司和本公司的附属公司)的董事总经理。从2012年7月到2018年10月，Poukalov先生在Kadmon担任越来越重要的职务，最近从2014年7月到2018年10月担任执行副总裁兼首席财务官。加入Kadmon之前，从2009年到2012年，他是Jefferies LLC医疗保健投资银行集团的成员，专注于生命科学和生物技术领域的公司。加入Jefferies LLC之前，他是UBS Investment Bank的成员，从2006年到2009年专注于医疗保健行业。Poukalov先生自2020年1月起担任Lyra Therapeutics的董事会成员。他持有Stony Brook University的电气工程学士学位。
Konstantin Poukalov has served as the Executive Chairman of LianBio board of directors since October 2019. Mr. Poukalov has served as a Managing Director at Perceptive Advisors, a life sciences-focused investment firm and affiliate of the Company, since March 2019. From July 2012 to October 2018 Mr. Poukalov served in roles of increasing responsibility at Kadmon, most recently serving as Executive Vice President and Chief Financial Officer from July 2014 to October 2018. Prior to joining Kadmon, Mr. Poukalov was a member of the healthcare investment banking group at Jefferies LLC from 2009 to 2012 focusing on companies across the life sciences and biotechnology sectors. Prior to Jefferies LLC, Mr. Poukalov was a member of UBS Investment Bank, focusing on the healthcare industry from 2006 to 2009. Mr. Poukalov has also served as a member of the boards of directors of Lyra Therapeutics since January 2020. Mr. Poukalov earned a bachelor's degree in electrical engineering from Stony Brook University. - Konstantin Poukalov自2019年10月起担任LianBio董事会执行主席。Poukalov先生自2019年3月起担任Perceptive Advisors(一家专注于生命科学的投资公司和本公司的附属公司)的董事总经理。从2012年7月到2018年10月，Poukalov先生在Kadmon担任越来越重要的职务，最近从2014年7月到2018年10月担任执行副总裁兼首席财务官。加入Kadmon之前，从2009年到2012年，他是Jefferies LLC医疗保健投资银行集团的成员，专注于生命科学和生物技术领域的公司。加入Jefferies LLC之前，他是UBS Investment Bank的成员，从2006年到2009年专注于医疗保健行业。Poukalov先生自2020年1月起担任Lyra Therapeutics的董事会成员。他持有Stony Brook University的电气工程学士学位。
- Konstantin Poukalov has served as the Executive Chairman of LianBio board of directors since October 2019. Mr. Poukalov has served as a Managing Director at Perceptive Advisors, a life sciences-focused investment firm and affiliate of the Company, since March 2019. From July 2012 to October 2018 Mr. Poukalov served in roles of increasing responsibility at Kadmon, most recently serving as Executive Vice President and Chief Financial Officer from July 2014 to October 2018. Prior to joining Kadmon, Mr. Poukalov was a member of the healthcare investment banking group at Jefferies LLC from 2009 to 2012 focusing on companies across the life sciences and biotechnology sectors. Prior to Jefferies LLC, Mr. Poukalov was a member of UBS Investment Bank, focusing on the healthcare industry from 2006 to 2009. Mr. Poukalov has also served as a member of the boards of directors of Lyra Therapeutics since January 2020. Mr. Poukalov earned a bachelor's degree in electrical engineering from Stony Brook University.
- Roderick Wong
-
Roderick Wong自2019年8月起担任董事。Wong博士自2010年以来担任RTW Investments，LP的管理合伙人兼首席投资官。黄博士此前于2018年12月至2019年12月担任Health Sciences Acquisition Corporation的总裁，首席执行官兼董事长。他自2015年7月起担任Rocket Pharmaceuticals，Inc.董事会主席，自2020年6月起担任AvidityBiosciences，Inc.董事会成员。Wong博士拥有杜克大学（Duke University）经济学学士学位，宾夕法尼亚大学医学院（University of Pennsylvania Medical School）医学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
Roderick Wong has served as Chairman of Rocket Pharmaceuticals, Inc. Board since January 2018 when he joined the Board in connection with the Reverse Merger. Dr. Wong served as the Chairman of the Board for Private Rocket from July 2015 until January 2018. Dr. Wong has over 15 years of healthcare investment experience. Since 2010 he has served as Managing Partner and Chief Investment Officer of RTW Investments, LP “RTW”, a healthcare-centered investment firm. Prior to RTW, Dr. Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and healthcare research roles at SAC Capital Company and Cowen & Company. Dr. Wong served on the Board of Directors of Penwest Pharmaceuticals in 2010. He received an MD from the University of Pennsylvania Medical School, received an MBA from Harvard Business School, and graduated with a BS in Economics from Duke University. - Roderick Wong自2019年8月起担任董事。Wong博士自2010年以来担任RTW Investments，LP的管理合伙人兼首席投资官。黄博士此前于2018年12月至2019年12月担任Health Sciences Acquisition Corporation的总裁，首席执行官兼董事长。他自2015年7月起担任Rocket Pharmaceuticals，Inc.董事会主席，自2020年6月起担任AvidityBiosciences，Inc.董事会成员。Wong博士拥有杜克大学（Duke University）经济学学士学位，宾夕法尼亚大学医学院（University of Pennsylvania Medical School）医学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
- Roderick Wong has served as Chairman of Rocket Pharmaceuticals, Inc. Board since January 2018 when he joined the Board in connection with the Reverse Merger. Dr. Wong served as the Chairman of the Board for Private Rocket from July 2015 until January 2018. Dr. Wong has over 15 years of healthcare investment experience. Since 2010 he has served as Managing Partner and Chief Investment Officer of RTW Investments, LP “RTW”, a healthcare-centered investment firm. Prior to RTW, Dr. Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and healthcare research roles at SAC Capital Company and Cowen & Company. Dr. Wong served on the Board of Directors of Penwest Pharmaceuticals in 2010. He received an MD from the University of Pennsylvania Medical School, received an MBA from Harvard Business School, and graduated with a BS in Economics from Duke University.
- Jean Frederic Colombel
-
Jean Frederic Colombel自2021年1月起担任董事。Colombel博士目前担任纽约伊坎医学院（Icahn School of Medicine）Leona and Harry B.Helmsley慈善信托炎症性肠病的医学教授和董事，他自2013年以来一直担任该职位。自2013年以来，Colombel博士还担任纽约伊坎医学院Susan and Leonard Feinstein炎症性肠病中心的联合主任。自2017年以来，Colombel博士一直担任纽约伊坎医学院任命，晋升和任期委员会成员。Colombel博士自2016年以来一直担任胃肠病学副编辑，并自2015年以来一直担任the Crohn’；S&Colitis Foundation of America的国家科学咨询委员会成员。Colombel博士拥有法国里尔第二大学的博士学位，法国巴黎第七大学的DEA（Diplome D’；Etudes Approfondies）和法国里尔第二大学的医学博士学位。
Jean Frederic Colombel has served as a director since January 2021. Dr. Colombel currently serves as a Professor of Medicine and Director of the Leona and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease, Icahn School of Medicine, New York, positions he has held since 2013. Since 2013 Dr. Colombel has also served as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine, New York. Since 2017 Dr. Colombel has served as a member of the Committee on Appointments, Promotions and Tenure at the Icahn School of Medicine, New York. Dr. Colombel has served as an associate editor of Gastroenterology since 2016 and has been a member of the National Scientific Advisory Committee at the Crohn’s & Colitis Foundation of America since 2015. Dr. Colombel holds an HDR Habilitation a Diriger les Recherches from Universite Lille II, France, a DEA (Diplome d’Etudes Approfondies) from Universite Paris VII, France, and an M.D. from Université Lille II, France. - Jean Frederic Colombel自2021年1月起担任董事。Colombel博士目前担任纽约伊坎医学院（Icahn School of Medicine）Leona and Harry B.Helmsley慈善信托炎症性肠病的医学教授和董事，他自2013年以来一直担任该职位。自2013年以来，Colombel博士还担任纽约伊坎医学院Susan and Leonard Feinstein炎症性肠病中心的联合主任。自2017年以来，Colombel博士一直担任纽约伊坎医学院任命，晋升和任期委员会成员。Colombel博士自2016年以来一直担任胃肠病学副编辑，并自2015年以来一直担任the Crohn’；S&Colitis Foundation of America的国家科学咨询委员会成员。Colombel博士拥有法国里尔第二大学的博士学位，法国巴黎第七大学的DEA（Diplome D’；Etudes Approfondies）和法国里尔第二大学的医学博士学位。
- Jean Frederic Colombel has served as a director since January 2021. Dr. Colombel currently serves as a Professor of Medicine and Director of the Leona and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease, Icahn School of Medicine, New York, positions he has held since 2013. Since 2013 Dr. Colombel has also served as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine, New York. Since 2017 Dr. Colombel has served as a member of the Committee on Appointments, Promotions and Tenure at the Icahn School of Medicine, New York. Dr. Colombel has served as an associate editor of Gastroenterology since 2016 and has been a member of the National Scientific Advisory Committee at the Crohn’s & Colitis Foundation of America since 2015. Dr. Colombel holds an HDR Habilitation a Diriger les Recherches from Universite Lille II, France, a DEA (Diplome d’Etudes Approfondies) from Universite Paris VII, France, and an M.D. from Université Lille II, France.
- Josep Bassaganya Riera
-
Josep Bassaganya Riera自我们于2017年1月成立以来一直担任我们的董事长，总裁兼首席执行官。Bassaganya-Riera博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的主任，从2008年10月开始担任BioTherapeutics Inc.的董事会主席。他此前曾于2008年10月至2017年9月担任BioTherapeutics的首席执行官，并于2002年12月至2020年5月担任弗吉尼亚理工大学免疫学研究教授。Bassaganya-Riera博士拥有Universitat Aut&242；Noma de Barcelona兽医学学位和Iowa State University营养和免疫学博士学位。
Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University. - Josep Bassaganya Riera自我们于2017年1月成立以来一直担任我们的董事长，总裁兼首席执行官。Bassaganya-Riera博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的主任，从2008年10月开始担任BioTherapeutics Inc.的董事会主席。他此前曾于2008年10月至2017年9月担任BioTherapeutics的首席执行官，并于2002年12月至2020年5月担任弗吉尼亚理工大学免疫学研究教授。Bassaganya-Riera博士拥有Universitat Aut&242；Noma de Barcelona兽医学学位和Iowa State University营养和免疫学博士学位。
- Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
- Christopher Garabedian
-
Christopher Garabedian，他一直担任我们董事会的成员（2010年6月以来），以及我们的总裁兼首席执行官（2011年1月以来）。他曾担任Celgene Corporation（一体化的上市全球生物制药公司）的企业战略的副总裁（从2007年7月到2010年12月），负责评估所有潜在的商业发展事务。从2005年11月到2007年6月，他担任早期生物制药公司的独立顾问。他曾任职Gilead Sciences公司（上市生物制药公司），担任多种全球领导职务，包括公司发展副总裁、营销副总裁，以及医务副总裁（从1997年到1998年，从1999年到2005年11月）。任职Gilead Sciences公司期间，他负责管理公司发展计划，包括项目组合评估和规划、并购和授权活动，并领导四个全球产品发布。他也曾担任COR Therapeutics公司（从1998年到1999年）和Abbott Laboratories公司（从1994年到1997年）的多种商业职务。他的生物制药生涯始于担任Migliara/Kaplan Associates公司的顾问（从1991年到1994年）。
Christopher Garabedian has served as a director since September 2017. He founded Xontogeny in June 2016 and serves as its Chairman and Chief Executive Officer. Mr. Garabedian also serves as a Senior Advisor at the Boston Consulting Group, a position he has held since January 2016 and as a Portfolio Manager at Perceptive Advisors, a position he has held since May 2017. He previously served as the President and Chief Executive Officer of Sarpeta Therapeutics, Inc. from January 2011 to March 2015 as well as a member of the board of directors from June 2010 to March 2015. Mr. Garabedian earned a B.S. in Marketing from the University of Maryland. - Christopher Garabedian，他一直担任我们董事会的成员（2010年6月以来），以及我们的总裁兼首席执行官（2011年1月以来）。他曾担任Celgene Corporation（一体化的上市全球生物制药公司）的企业战略的副总裁（从2007年7月到2010年12月），负责评估所有潜在的商业发展事务。从2005年11月到2007年6月，他担任早期生物制药公司的独立顾问。他曾任职Gilead Sciences公司（上市生物制药公司），担任多种全球领导职务，包括公司发展副总裁、营销副总裁，以及医务副总裁（从1997年到1998年，从1999年到2005年11月）。任职Gilead Sciences公司期间，他负责管理公司发展计划，包括项目组合评估和规划、并购和授权活动，并领导四个全球产品发布。他也曾担任COR Therapeutics公司（从1998年到1999年）和Abbott Laboratories公司（从1994年到1997年）的多种商业职务。他的生物制药生涯始于担任Migliara/Kaplan Associates公司的顾问（从1991年到1994年）。
- Christopher Garabedian has served as a director since September 2017. He founded Xontogeny in June 2016 and serves as its Chairman and Chief Executive Officer. Mr. Garabedian also serves as a Senior Advisor at the Boston Consulting Group, a position he has held since January 2016 and as a Portfolio Manager at Perceptive Advisors, a position he has held since May 2017. He previously served as the President and Chief Executive Officer of Sarpeta Therapeutics, Inc. from January 2011 to March 2015 as well as a member of the board of directors from June 2010 to March 2015. Mr. Garabedian earned a B.S. in Marketing from the University of Maryland.
高管简历
中英对照 | 中文 | 英文- Josep Bassaganya Riera
Josep Bassaganya Riera自我们于2017年1月成立以来一直担任我们的董事长，总裁兼首席执行官。Bassaganya-Riera博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的主任，从2008年10月开始担任BioTherapeutics Inc.的董事会主席。他此前曾于2008年10月至2017年9月担任BioTherapeutics的首席执行官，并于2002年12月至2020年5月担任弗吉尼亚理工大学免疫学研究教授。Bassaganya-Riera博士拥有Universitat Aut&242；Noma de Barcelona兽医学学位和Iowa State University营养和免疫学博士学位。
Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.- Josep Bassaganya Riera自我们于2017年1月成立以来一直担任我们的董事长，总裁兼首席执行官。Bassaganya-Riera博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的主任，从2008年10月开始担任BioTherapeutics Inc.的董事会主席。他此前曾于2008年10月至2017年9月担任BioTherapeutics的首席执行官，并于2002年12月至2020年5月担任弗吉尼亚理工大学免疫学研究教授。Bassaganya-Riera博士拥有Universitat Aut&242；Noma de Barcelona兽医学学位和Iowa State University营养和免疫学博士学位。
- Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
- Raquel Hontecillas
Raquel Hontecillas自2017年1月成立以来一直担任我们的首席科学官。Hontecillas博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的联席主管，从2008年10月开始担任BioTherapeutics，Inc.的首席科学官。她此前曾于2008年7月至2020年7月担任弗吉尼亚理工大学免疫学研究教授。Hontecillas博士拥有西班牙马德里康普卢滕斯大学（Universidad Complutense University de Madrid）兽医学学位和爱荷华州立大学（Iowa State University）免疫学博士学位。
Raquel Hontecillas has served as our Chief Scientific Officer since our founding in January 2017. Dr. Hontecillas is the Co-Director of the Nutritional Immunology and Molecular Medicine Laboratory, a position she has held since July 2002 and the Chief Scientific Officer of Biotherapeutics, Inc., a position she has held since October 2008. She previously served as a Research Professor of Immunology at Virginia Tech from July 2008 to July 2020. Dr. Hontecillas holds a degree in Veterinary Medicine from Universidad Complutense University de Madrid, Spain and a Ph.D. in Immunology from Iowa State University.- Raquel Hontecillas自2017年1月成立以来一直担任我们的首席科学官。Hontecillas博士从2002年7月开始担任营养免疫学与分子医学实验室（Nutritional Immunology and Molecular Medicine Laboratory）的联席主管，从2008年10月开始担任BioTherapeutics，Inc.的首席科学官。她此前曾于2008年7月至2020年7月担任弗吉尼亚理工大学免疫学研究教授。Hontecillas博士拥有西班牙马德里康普卢滕斯大学（Universidad Complutense University de Madrid）兽医学学位和爱荷华州立大学（Iowa State University）免疫学博士学位。
- Raquel Hontecillas has served as our Chief Scientific Officer since our founding in January 2017. Dr. Hontecillas is the Co-Director of the Nutritional Immunology and Molecular Medicine Laboratory, a position she has held since July 2002 and the Chief Scientific Officer of Biotherapeutics, Inc., a position she has held since October 2008. She previously served as a Research Professor of Immunology at Virginia Tech from July 2008 to July 2020. Dr. Hontecillas holds a degree in Veterinary Medicine from Universidad Complutense University de Madrid, Spain and a Ph.D. in Immunology from Iowa State University.
- Jyoti Chauhan
Jyoti Chauhan自2019年8月起担任我们的全球临床运营和监管事务执行董事。她此前曾于2018年2月至2018年7月担任我们的临床项目经理，并于2018年7月至2019年8月担任我们的临床运营和监管事务计划总监。Chauhan女士曾于2018年3月至2018年8月担任NexImmune，Inc.监管事务经理，2017年9月至2018年3月担任国际杀微生物剂伙伴关系高级监管事务专家，并于技术资源国际担任监管事务专家，2016年3月至2017年9月，她目前担任南凌科技公司的负责人，自2015年10月起担任该职位。Chauhan女士拥有Hemwati Nandan Bahuguna Garhwal University的化学、植物学和动物学生物技术学士学位，以及Narsee Monjee Institute of Management Studies的制药科学硕士学位。
Jyoti Chauhan has served as our Executive Director of Global Clinical Operations and Regulatory Affairs since August 2019. She previously served as our Clinical Project Manager from February 2018 to July 2018 and our Program Director, Clinical Operations and Regulatory Affairs from July 2018 to August 2019. Ms. Chauhan previously served as the Manager of Regulatory Affairs at NexImmune, Inc. from March 2018 to August 2018 the Senior Regulatory Affairs Specialist at the International Partnership for Microbicides from September 2017 to March 2018 and the Regulatory Affairs Specialist at Technical Resources International, Inc. from March 2016 to September 2017 and currently serves as a Principal at Nova Technology Inc., a position she has held since October 2015. Ms. Chauhan holds a B.S. in Biotechnology with Chemistry, Botany and Zoology from Hemwati Nandan Bahuguna Garhwal University and a M.S. in Pharmaceutical Sciences from the Narsee Monjee Institute of Management Studies.- Jyoti Chauhan自2019年8月起担任我们的全球临床运营和监管事务执行董事。她此前曾于2018年2月至2018年7月担任我们的临床项目经理，并于2018年7月至2019年8月担任我们的临床运营和监管事务计划总监。Chauhan女士曾于2018年3月至2018年8月担任NexImmune，Inc.监管事务经理，2017年9月至2018年3月担任国际杀微生物剂伙伴关系高级监管事务专家，并于技术资源国际担任监管事务专家，2016年3月至2017年9月，她目前担任南凌科技公司的负责人，自2015年10月起担任该职位。Chauhan女士拥有Hemwati Nandan Bahuguna Garhwal University的化学、植物学和动物学生物技术学士学位，以及Narsee Monjee Institute of Management Studies的制药科学硕士学位。
- Jyoti Chauhan has served as our Executive Director of Global Clinical Operations and Regulatory Affairs since August 2019. She previously served as our Clinical Project Manager from February 2018 to July 2018 and our Program Director, Clinical Operations and Regulatory Affairs from July 2018 to August 2019. Ms. Chauhan previously served as the Manager of Regulatory Affairs at NexImmune, Inc. from March 2018 to August 2018 the Senior Regulatory Affairs Specialist at the International Partnership for Microbicides from September 2017 to March 2018 and the Regulatory Affairs Specialist at Technical Resources International, Inc. from March 2016 to September 2017 and currently serves as a Principal at Nova Technology Inc., a position she has held since October 2015. Ms. Chauhan holds a B.S. in Biotechnology with Chemistry, Botany and Zoology from Hemwati Nandan Bahuguna Garhwal University and a M.S. in Pharmaceutical Sciences from the Narsee Monjee Institute of Management Studies.